McKinnon C, Nandhabalan M, Murray SA, Plaha P (2021) Glioblastoma: clinical presentation, diagnosis, and management. BMJ 374:n1560

Article  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352(10):987–996

Article  CAS  PubMed  Google Scholar 

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C et al (2017) Short-Course radiation plus Temozolomide in elderly patients with glioblastoma. N Engl J Med 376(11):1027–1037

Article  CAS  PubMed  Google Scholar 

Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926

Article  PubMed  Google Scholar 

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant Astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707–715

Article  CAS  PubMed  Google Scholar 

Laigle-Donadey F, Metellus P, Guyotat J, Menei P, Proust F, Dufour H et al (2023) Surgery for glioblastomas in the elderly: an association des Neuro-oncologues d’expression Francaise (ANOCEF) trial. J Neurosurg 138(5):1199–1205

Article  PubMed  Google Scholar 

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453–461

Article  PubMed  Google Scholar 

Blakstad H, Mendoza Mireles EE, Heggebo LC, Magelssen H, Sprauten M, Johannesen TB et al (2024) Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study. Neurooncol Pract 11(1):36–45

PubMed  Google Scholar 

Pouleau HB, Sadeghi N, Baleriaux D, Melot C, De Witte O, Lefranc F (2012) High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40(4):923–928

Article  PubMed  Google Scholar 

Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S et al (2017) Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Med 6(12):2858–2866

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36–42

Article  PubMed  Google Scholar 

Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A (2018) Incidence of tumour progression and pseudoprogression in High-Grade gliomas: a systematic review and Meta-Analysis. Clin Neuroradiol 28(3):401–411

Article  PubMed  Google Scholar 

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972

Article  PubMed  Google Scholar 

Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B (2020) Response assessment in Neuro-Oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am J Neuroradiol 41(1):10–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Mieghem E, Wozniak A, Geussens Y, Menten J, De Vleeschouwer S, Van Calenbergh F et al (2013) Defining pseudoprogression in glioblastoma multiforme. Eur J Neurol 20(10):1335–1341

Article  PubMed  Google Scholar 

Hygino da Cruz LC Jr., Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978–1985

Article  PubMed  PubMed Central  Google Scholar 

Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI (2018) Radiation Necrosis, Pseudoprogression, Pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging 2018:6828396

Article  PubMed  PubMed Central  Google Scholar 

Kang HC, Kim CY, Han JH, Choe GY, Kim JH, Kim JH et al (2011) Pseudoprogression in patients with malignant gliomas treated with concurrent Temozolomide and radiotherapy: potential role of p53. J Neurooncol 102(1):157–162

Article  CAS  PubMed  Google Scholar 

Gahramanov S, Varallyay C, Tyson RM, Lacy C, Fu R, Netto JP et al (2014) Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme May predict improved survival. CNS Oncol 3(6):389–400

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H et al (2018) Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM. J Neurooncol 139(1):145–152

Article  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14(2):307–320

Article  PubMed  PubMed Central  Google Scholar 

Young RJ, Gupta A, Shah AD, Graber JJ, Chan TA, Zhang Z et al (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37(1):41–49

Article  PubMed  Google Scholar 

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197

Article  PubMed  Google Scholar 

Li H, Li J, Cheng G, Zhang J, Li X (2016) IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg 151:31–36

Article  PubMed  Google Scholar 

Li M, Ren X, Dong G, Wang J, Jiang H, Yang C et al (2021) Distinguishing pseudoprogression from true early progression in isocitrate dehydrogenase Wild-Type glioblastoma by interrogating Clinical, Radiological, and molecular features. Front Oncol 11:627325

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hagiwara A, Schlossman J, Shabani S, Raymond C, Tatekawa H, Abrey LE et al (2022) Incidence, molecular characteristics, and imaging features of clinically-defined pseudoprogression in newly diagnosed glioblastoma treated with chemoradiation. J Neurooncol 159(3):509–518

Article  PubMed  Google Scholar 

Motegi H, Kamoshima Y, Terasaka S, Kobayashi H, Yamaguchi S, Tanino M et al (2013) IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with Temozolomide and radiotherapy. Brain Tumor Pathol 30(2):67–72

Article  CAS  PubMed  Google Scholar 

Xi J, Hassan B, Katumba RGN, Khaddour K, Govindan A, Luo J et al (2021) The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma. BMC Cancer 21(1):285

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M et al (2016) Identification of biomarkers for Pseudo and true progression of GBM based on radiogenomics study. Oncotarget 7(34):55377–55394

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging 48(3):571–589

Article  PubMed